Compare JRSH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | FEMY |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 37.2M |
| IPO Year | 2017 | 2021 |
| Metric | JRSH | FEMY |
|---|---|---|
| Price | $3.00 | $0.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $5.50 |
| AVG Volume (30 Days) | 22.5K | ★ 448.1K |
| Earning Date | 02-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | ★ 56.25 | 8.60 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $145,812,006.00 | $1,629,108.00 |
| Revenue This Year | $11.64 | $59.47 |
| Revenue Next Year | $10.06 | $150.54 |
| P/E Ratio | $20.07 | ★ N/A |
| Revenue Growth | 24.43 | ★ 51.97 |
| 52 Week Low | $2.81 | $0.31 |
| 52 Week High | $3.64 | $1.45 |
| Indicator | JRSH | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 41.49 |
| Support Level | $2.87 | $0.48 |
| Resistance Level | $3.16 | $0.58 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.77 | 12.22 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.